The relation between resting heart rate and cancer incidence, cancer mortality and all-cause mortality in patients with manifest vascular disease

Cancer Epidemiology

Volumn 38, Issue 6, 2014, Pages 715-721

  van Kruijsdijk, Rob C M ^a   van der Graaf, Yolanda ^a   Bemelmans, Remy H H ^a   Nathoe, Hendrik M ^a   Peeters, Petra H M ^a   Visseren, Frank L J ^a   Doevendans, P A ^a   Algra, A ^a   van der Graaf, Y ^a   Grobbee, D E ^a   Rutten, G E H M ^a   Kappelle, L J ^a   Mali, W P T M ^a   MollMoll, F L ^a   Visseren, F L J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cancer; Cardiovascular disease; Mortality; Resting heart rate

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; PROSTATE CANCER; RESTING HEART RATE; VASCULAR DISEASE; HEART RATE; INCIDENCE; MIDDLE AGED; MORTALITY; NEOPLASM; PHYSIOLOGY; RISK FACTOR;

COHORT STUDIES; FEMALE; HEART RATE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; RISK FACTORS; VASCULAR DISEASES;

EID: 84912058312     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2014.09.004     Document Type: Article

References (32)

1. Grassi G., Vailati S., Bertinieri G., Seravalle G., Stella M.L., Dell'Oro R., et al. Heart rate as marker of sympathetic activity. J Hypertens 1998, 16:1635-1639.
2. Batty G.D., Shipley M.J., Kivimaki M., Marmot M., Davey Smith G. Walking pace, leisure time physical activity, and resting heart rate in relation to disease-specific mortality in London: 40 years follow-up of the original Whitehall study. An update of our work with professor Jerry N. Morris (1910-2009). Ann Epidemiol 2010, 20:661-669.
3. Bemelmans R.H., van der Graaf Y., Nathoe H.M., Wassink A.M., Vernooij J.W., Spiering W., et al. The risk of resting heart rate on vascular events and mortality in vascular patients. Int J Cardiol 2013, 168:1410-1415.
4. Greenland P., Daviglus M.L., Dyer A.R., Liu K., Huang C.F., Goldberger J.J., et al. Resting heart rate is a risk factor for cardiovascular and noncardiovascular mortality: the Chicago Heart Association Detection Project in Industry. Am J Epidemiol 1999, 149:853-862.
5. Kristal-Boneh E., Silber H., Harari G., Froom P. The association of resting heart rate with cardiovascular, cancer and all-cause mortality. Eight year follow-up of 3527 male Israeli employees (the CORDIS Study). Eur Heart J 2000, 21:116-124.
6. Tverdal A., Hjellvik V., Selmer R. Heart rate and mortality from cardiovascular causes: a 12 year follow-up study of 379,843 men and women aged 40-45 years. Eur Heart J 2008, 29:2772-2781.
7. Jouven X., Escolano S., Celermajer D., Empana J.P., Bingham A., Hermine O., et al. Heart rate and risk of cancer death in healthy men. PLoS ONE 2011, 6:e21310.
8. Blair S.N., Kohl H.W., Paffenbarger R.S., Clark D.G., Cooper K.H., Gibbons L.W. Physical fitness and all-cause mortality. A prospective study of healthy men and women. J Am Med Assoc 1989, 262(17):2395-2401.
9. Festa A., D'Agostino R., Hales C.N., Mykkanen L., Haffner S.M. Heart rate in relation to insulin sensitivity and insulin secretion in nondiabetic subjects. Diabetes Care 2000, 23:624-628.
10. Rogowski O., Shapira I., Shirom A., Melamed S., Toker S., Berliner S. Heart rate and microinflammation in men: a relevant atherothrombotic link. Heart 2007, 93:940-944.
11. van Kruijsdijk R.C., van der Wall E., Visseren F.L. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev 2009, 18:2569-2578.
12. Cole S.W., Sood A.K. Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res 2012, 18:1201-1206.
13. Persky V., Dyer A.R., Leonas J., Stamler J., Berkson D.M., Lindberg H.A., et al. Heart rate: a risk factor for cancer?. Am J Epidemiol 1981, 114:477-487.
14. van Kruijsdijk R.C., van der Graaf Y., Peeters P.H., Visseren F.L. Cancer risk in patients with manifest vascular disease: effects of smoking, obesity, and metabolic syndrome. Cancer Epidemiol Biomarkers Prev 2013, 22:1267-1277.
15. van Kruijsdijk RC, van der Graaf Y, Koffijberg H, de Borst GL, Nathoe HM, L.J. K, et al. Cause-specific mortality and years of life lost in patients with different manifestations of vascular disease. Submitted for publication.
16. Simons P.C., Algra A., van de Laak M.F., Grobbee D.E., van der Graaf Y. Second manifestations of ARTerial disease (SMART) study: rationale and design. Eur J Epidemiol 1999, 15:773-781.
17. Ainsworth B.E., Haskell W.L., Whitt M.C., Irwin M.L., Swartz A.M., Strath S.J., et al. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc 2000, 32:S498-S504.
18. The Netherlands Cancer Registry [cited June 2012]. Available from: . http://www.cijfersoverkanker.nl/.
19. Hsieh F.Y., Lavori P.W. Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Control Clin Trials 2000, 21:552-560.
20. Donders A.R., van der Heijden G.J., Stijnen T., Moons K.G. Review: a gentle introduction to imputation of missing values. J Clin Epidemiol 2006, 59:1087-1091.
21. Fine J.P., Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
22. Lau B., Cole S.R., Gange S.J. Competing risk regression models for epidemiologic data. Am J Epidemiol 2009, 170:244-256.
23. Cerhan J.R., Pavuk M., Wallace R.B. Positive association between resting pulse and cancer incidence in current and former smokers. Ann Epidemiol 1999, 9:34-44.
24. Fitzpatrick A.L., Daling J.R., Furberg C.D., Kronmal R.A., Weissfeld J.L. Hypertension, heart rate, use of antihypertensives, and incident prostate cancer. Ann Epidemiol 2001, 11:534-542.
25. Goldstein S. Beta-blocking drugs and coronary heart disease. Cardiovascular drugs and therapy /sponsored by the International Society of Cardiovascular Pharmacotherapy 1997, 11(Suppl. 1):219-225.
26. Mikkelsen K.L., Wiinberg N., Hoegholm A., Christensen H.R., Bang L.E., Nielsen P.E., et al. Smoking related to 24-h ambulatory blood pressure and heart rate: a study in 352 normotensive Danish subjects. Am J Hypertens 1997, 10:483-491.
27. Fox K., Borer J.S., Camm A.J., Danchin N., Ferrari R., Lopez Sendon J.L., et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007, 50:823-830.
28. Reil J.C., Custodis F., Swedberg K., Komajda M., Borer J.S., Ford I., et al. Heart rate reduction in cardiovascular disease and therapy. Clin Res Cardiol 2011, 100:11-19.
29. Fox K., Ford I., Steg P.G., Tendera M., Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:807-816.
30. Swedberg K., Komajda M., Bohm M., Borer J.S., Ford I., Dubost-Brama A., et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010, 376:875-885.
31. Stewart R., Held C., Brown R., Vedin O., Hagstrom E., Lonn E., et al. Physical activity in patients with stable coronary heart disease: an international perspective. Eur Heart J 2013, 34:3286-3293.
32. van der Sanden G.A., Coebergh J.W., Schouten L.J., Visser O., van Leeuwen F.E. Cancer incidence in The Netherlands in 1989 and 1990: first results of the nationwide Netherlands cancer registry. Coordinating Committee for Regional Cancer Registries. Eur J Cancer 1995, 31A:1822-1829.